Login to Your Account

Pharma: Other News To Note

Friday, November 22, 2013

• Pfizer Inc., of New York, said the FDA granted regular approval for Xalkori (crizotinib) for use in patients with metastatic ALK-positive non-small-cell lung cancer as detected by an FDA-approved test. Xalkori previously gained accelerated approval in August 2011.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription